The release of Semaglutide at a higher level represents a notable advance in addressing type 2 diabetes. Before, lower doses were typically administered, but this additional formulation delivers the chance for greater glucose control in certain individuals. Clinicians are assessing its efficacy and well-being profile, especially in patients who … Read More